64 related articles for article (PubMed ID: 19651373)
1. The clinical performance of Invader technology and SurePath when detecting the presence of high-risk HPV cervical infection.
Harvey M; Stout S; Starkey CR; Hendren R; Holt S; Miller GC
J Clin Virol; 2009 Jul; 45 Suppl 1():S79-83. PubMed ID: 19651373
[TBL] [Abstract][Full Text] [Related]
2. An HPV 16, 18, and 45 genotyping test based on Hybrid Capture technology.
Thai H; Rangwala S; Gay T; Keating K; McLeod S; Nazarenko I; O'Neil D; Pfister D; Loeffert D
J Clin Virol; 2009 Jul; 45 Suppl 1():S93-7. PubMed ID: 19651375
[TBL] [Abstract][Full Text] [Related]
3. A comparative review of laboratory-developed tests utilizing Invader HPV analyte-specific reagents for the detection of high-risk human papillomavirus.
Stillman MJ; Day SP; Schutzbank TE
J Clin Virol; 2009 Jul; 45 Suppl 1():S73-7. PubMed ID: 19651372
[TBL] [Abstract][Full Text] [Related]
4. The next-generation Hybrid Capture High-Risk HPV DNA assay on a fully automated platform.
Eder PS; Lou J; Huff J; Macioszek J
J Clin Virol; 2009 Jul; 45 Suppl 1():S85-92. PubMed ID: 19651374
[TBL] [Abstract][Full Text] [Related]
5. High performance of a new PCR-based urine assay for HPV-DNA detection and genotyping.
Tanzi E; Bianchi S; Fasolo MM; Frati ER; Mazza F; Martinelli M; Colzani D; Beretta R; Zappa A; Orlando G
J Med Virol; 2013 Jan; 85(1):91-8. PubMed ID: 23097252
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection.
Halfon P; Benmoura D; Agostini A; Khiri H; Penaranda G; Martineau A; Blanc B
J Clin Virol; 2010 Aug; 48(4):246-50. PubMed ID: 20541966
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of AMPLICOR HPV PCR and Linear Array assays on SurePath liquid-based Pap samples for the detection of high-risk HPV genotypes.
Chernesky M; Jang D; Portillo E; Smieja M; Chong S; Buracond S; Klingel M; El Sebai R; Kapala J; Patel J; Biers K; Harroun N; Doucette C; Sumner J
J Clin Virol; 2011 Mar; 50(3):201-4. PubMed ID: 21195020
[TBL] [Abstract][Full Text] [Related]
8. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses.
Arbyn M; Sasieni P; Meijer CJ; Clavel C; Koliopoulos G; Dillner J
Vaccine; 2006 Aug; 24 Suppl 3():S3/78-89. PubMed ID: 16950021
[TBL] [Abstract][Full Text] [Related]
9. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
10. Introduction of human papillomavirus DNA screening in the world: 15 years of experience.
Castle PE; de Sanjosé S; Qiao YL; Belinson JL; Lazcano-Ponce E; Kinney W
Vaccine; 2012 Nov; 30 Suppl 5():F117-22. PubMed ID: 23199954
[TBL] [Abstract][Full Text] [Related]
11. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types.
Castle PE; Schiffman M; Burk RD; Wacholder S; Hildesheim A; Herrero R; Bratti MC; Sherman ME; Lorincz A
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1394-9. PubMed ID: 12433717
[TBL] [Abstract][Full Text] [Related]
12. [Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN)].
Sotlar K; Diemer D; Stubner A; Menton S; Menton M; Dietz K; Wallwiener D; Bültmann B
Verh Dtsch Ges Pathol; 2005; 89():195-200. PubMed ID: 18035691
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of the xMAP technology in detection of high-risk human papillomavirus].
Liao GD; Zhang XY; Gao YH; Liu B; Liu X; Li LK; Chen F; Bian ML; Chen W; Qiao YL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):603-7. PubMed ID: 18051713
[TBL] [Abstract][Full Text] [Related]
14. Rapid detection of the most common high-risk human papillomaviruses by loop-mediated isothermal amplification.
Saetiew C; Limpaiboon T; Jearanaikoon P; Daduang S; Pientong C; Kerdsin A; Daduang J
J Virol Methods; 2011 Dec; 178(1-2):22-30. PubMed ID: 21903136
[TBL] [Abstract][Full Text] [Related]
15. New technologies and procedures for cervical cancer screening.
Cuzick J; Bergeron C; von Knebel Doeberitz M; Gravitt P; Jeronimo J; Lorincz AT; J L M Meijer C; Sankaranarayanan R; J F Snijders P; Szarewski A
Vaccine; 2012 Nov; 30 Suppl 5():F107-16. PubMed ID: 23199953
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HPV sign genotyping test with INNO-LiPA HPV genotyping extra assay on histologic and cytologic cervical specimens.
Barbieri D; Nocera M; Gallinella G; Gentilomi GA; Plazzi M; Costa S; Santini D; Venturoli S
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):43-8. PubMed ID: 22717156
[TBL] [Abstract][Full Text] [Related]
17. Comparison of urine and cervical samples for detecting human papillomavirus (HPV) with the Cobas 4800 HPV test.
Bernal S; Palomares JC; Artura A; Parra M; Cabezas JL; Robles A; Martín Mazuelos E
J Clin Virol; 2014 Dec; 61(4):548-52. PubMed ID: 25453566
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the digene HPV hybrid capture 2 assay for detection of high-risk HPV DNA.
Ginocchio CC; Barth D; Zhang F
J Clin Microbiol; 2008 May; 46(5):1641-6. PubMed ID: 18367578
[TBL] [Abstract][Full Text] [Related]
19. Patient safety and the next generation of HPV DNA tests.
Simon K; Kondratovich MV; Hojvat S; Gutierrez A
Am J Clin Pathol; 2011 May; 135(5):798-9; author reply 799-803. PubMed ID: 21502437
[No Abstract] [Full Text] [Related]
20. Principles and analytical performance of Abbott RealTime High Risk HPV test.
Huang S; Tang N; Mak WB; Erickson B; Salituro J; Li Y; Krumpe E; Schneider G; Yu H; Robinson J; Abravaya K
J Clin Virol; 2009 Jul; 45 Suppl 1():S13-7. PubMed ID: 19651363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
